Background: Neutrophil Gelatinase-associated Lipocalin (NGAL) has generated great interest as a novel biomarker for the timely detection of Acute Kidney Injury (AKI). This study, therefore, investigated NGAL as a predictive marker for acute kidney injury among sickle cell subjects.
Materials and methods: A total of fifty (50) sickle cell subjects aged 18-60 years and attending the sickle cell clinic of Federal Medical Centre, Owo were randomly recruited along with twenty-five (25) apparently healthy age and sexmatched non-sickle cell subjects attending the family medicine outpatient clinic of the hospital as control for the study. Plasma levels of NGAL were assessed using an Enzyme-Linked Immunosorbent Assay (ELISA) kit, while urea and creatinine were determined by standard spectrophotometric method. The results were statistically analyzed for significance at p<0.05 using one-way analysis of variance (ANOVA).
Results: NGAL and urea plasma levels were significantly (p<0.05) increased in the steady and vaso-occlusive (VOC) sickle cell subjects, glomerular filtration rate showed significant (p<0.05) reduction in both steady and VOC groups compared to the normal healthy control. The levels of urea and creatinine were increased significantly (p<0.05) in the VOC sickle cell group compared with the steady sickle cell group, whereas circulating levels of NGAL showed a significant (p<0.05) reduction in VOC sickle cell group compared with the steady sickle cell group. NGAL revealed an excellent higher area under the receiver operating curve than urea and creatinine.
Conclusion: NGAL was shown to be a sensitive tool, an early biomarker for acute kidney injury in sickle cell subjects and clinically significant for its wide availability, easy accessibility, and sensitivity in aiding early detection with a dynamic wide range for routine assessment in the management of SCD.
Adedeji David Atere, Olumide Faith Ajani, David Bolaji Akinbo, Omobolaji Adewumi Adeosun and Odiaka Mark Anombem
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2019 All rights reserved. iMedPub LTD Last revised : March 20, 2019